STAT

SEPTEMBER 12, 2024

The announcement was made ahead of a meeting being held by Moderna on Thursday to update investors on its research and development efforts. The company also said that it plans to break even by 2028, when it expects it will reach annual sales of $6 billion. Continue to STAT+ to read the full story…

Drug Development 332

Drug Development Vaccines 332

Pharmaceutical Technology

MAY 30, 2023

According to GlobalData’s Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 are projected to attain blockbuster status or near-blockbuster status by 2028 with US company dominance. These drugs are set to make a combined $4.34bn in sales in 2028.

Vaccines 105

Vaccines Drug Development 105

European Pharmaceutical Review

NOVEMBER 1, 2023

In July 2022, the World Health Organization (WHO) released its inaugural report on the pipeline of vaccines currently in development to prevent infections caused by antimicrobial resistance (AMR) bacterial pathogens. WHO referred to 61 bacterial vaccine candidates in diverse stages of clinical development.

Vaccines 115

Vaccines Immunity Immunization Drug Development 115

Pharmaceutical Technology

APRIL 27, 2023

The successful development and deployment of the mRNA-based COVID-19 vaccines has catalysed the biopharma industry and paved the way to expand this drug modality to new therapeutic areas. billion by 2028. Excluding vaccines, there are five mRNA therapeutic products in clinical trial development as of November 2022.

Vaccines 52

Vaccines Drug Development Documentation Communication 52

European Pharmaceutical Review

MARCH 12, 2025

MSD has announced it has opened a new $1 billion vaccine manufacturing facility at its site in Durham, North Carolina, US. MSD shared that a further $8 billion of US capital investment is anticipated by 2028.

Research Laboratories 52

Research Laboratories Vaccines Drug Development 52